1,2-Dierucoyl-sn-glycero-3-phosphocholine (CAS 51779-95-4) Ultimate Product Guide
Table of Contents
- 1. Product Specifications & Comparative Analysis
- 2. Key Applications & Functional Advantages
- 3. Industry Implementation Scenarios
- 4. Verified Client Case Studies
- 5. Technical Consultation & Quotation
1. Product Specifications & Comparative Analysis
| Parameter | Specification | Competitor A | Competitor B |
|---|---|---|---|
| CAS Number | 51779-95-4 | N/A | N/A |
| Molecular Formula | C52H100NO8P | Different backbone | Shorter chain |
| Purity | ≥99% (HPLC) | 95-98% | 90-95% |
| Phase Transition Temp | 42-45°C | 38-40°C | 35-37°C |
2. Key Applications & Functional Advantages
Pharmaceutical Applications
- Liposomal drug delivery systems
- mRNA vaccine encapsulation
- Targeted cancer therapeutics
Industrial Advantages
- Superior membrane stability vs. DOPC/DMPC
- Low peroxide formation (<0.1 mEq/kg)
- Cold-chain stability: 2-8°C for 24 months
3. Industry Implementation Scenarios
Scenario 1: Gene Therapy Vectors
Used in CRISPR-Cas9 lipid nanoparticles (LNPs) to achieve 92% transfection efficiency in vivo.
Scenario 2: Dermatological Formulations
Enables transdermal delivery of retinoic acid with 3× bioavailability improvement.
4. Verified Client Case Studies
Case Study 1: Oncology Biotech (2023)
| Client | OncoTarget Therapeutics |
|---|---|
| Challenge | Low encapsulation efficiency (<65%) for paclitaxel |
| Solution | 20% w/w 1,2-Dierucoyl PC in liposome matrix |
| Result | 89% encapsulation, 50% tumor volume reduction in murine models |
Case Study 2: Vaccine Developer (2024)
| Client | VaxGen Global |
|---|---|
| Challenge | mRNA integrity loss during freeze-thaw cycles |
| Solution | Optimized LNP formulation with 30% Dierucoyl PC |
| Result |
5. Technical Consultation & Quotation
Contact our lipid specialists for:
- Custom purity specifications (95%-99.9%)
- GMP-grade manufacturing options
- Technical support for formulation development
Email: info@vivalr.com
Tel: (86) 15866781826



评论
目前还没有评论。